drugset
drugset / Trial / NCT01650597

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

NCT01650597 ↗

Phase 1 Completed 29 enrolled Janssen-Cilag International NV
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single ascending doses as well as repeated doses of JNJ-42165279 in healthy male participants.

Timeline

Start
2011-08
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-42165279 Small molecule 2.5 mg Oral
Subject JNJ-42165279 Small molecule 10 mg Oral
Subject JNJ-42165279 Small molecule 30 mg Oral
Subject JNJ-42165279 Small molecule 100 mg Oral
Subject JNJ-42165279 Small molecule 250 mg Oral
Subject JNJ-42165279 Small molecule 500 mg Oral

Indications

No indication recorded.